MX2022008875A - Inhibidores terapeuticos de tirosina quinasa para esclerosis multiple recidivante (emr). - Google Patents
Inhibidores terapeuticos de tirosina quinasa para esclerosis multiple recidivante (emr).Info
- Publication number
- MX2022008875A MX2022008875A MX2022008875A MX2022008875A MX2022008875A MX 2022008875 A MX2022008875 A MX 2022008875A MX 2022008875 A MX2022008875 A MX 2022008875A MX 2022008875 A MX2022008875 A MX 2022008875A MX 2022008875 A MX2022008875 A MX 2022008875A
- Authority
- MX
- Mexico
- Prior art keywords
- tyrosine kinase
- therapeutic
- multiple sclerosis
- rms
- kinase inhibitors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062963238P | 2020-01-20 | 2020-01-20 | |
| US202062970502P | 2020-02-05 | 2020-02-05 | |
| US202063013895P | 2020-04-22 | 2020-04-22 | |
| PCT/US2021/013883 WO2021150476A1 (en) | 2020-01-20 | 2021-01-19 | Therapeutic tyrosine kinase inhibitors for relapsing multiple sclerosis (rms) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022008875A true MX2022008875A (es) | 2022-08-11 |
Family
ID=74626161
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022008875A MX2022008875A (es) | 2020-01-20 | 2021-01-19 | Inhibidores terapeuticos de tirosina quinasa para esclerosis multiple recidivante (emr). |
Country Status (12)
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3168146A1 (en) * | 2020-01-20 | 2021-07-29 | Genzyme Corporation | Therapeutic tyrosine kinase inhibitors for relapsing multiple sclerosis (rms) |
| CA3201936A1 (en) * | 2020-12-10 | 2022-06-16 | Minhua Chen | Crystal form of tolebrutinib and preparation method thereof |
| IL303834A (en) | 2020-12-23 | 2023-08-01 | Genzyme Corp | 4-amino-3-(4-phenoxyphenyl)-1,3-dihydro-2H-imidazo[4,5-C]pyridin-2-one derivatives and their salts |
| CN117295735B (zh) * | 2021-04-23 | 2026-05-12 | 杭州领业医药科技有限公司 | Tolebrutinib晶型、无定型及其制备方法和用途 |
| CN117412749A (zh) * | 2021-05-21 | 2024-01-16 | 杭州领业医药科技有限公司 | Tolebrutinib盐及其晶型、其制备方法、其药物组合物和用途 |
| WO2022257845A1 (zh) * | 2021-06-11 | 2022-12-15 | 苏州科睿思制药有限公司 | Tolebrutinib的晶型及其制备方法和用途 |
| WO2023280132A1 (zh) * | 2021-07-06 | 2023-01-12 | 苏州晶云药物科技股份有限公司 | 氧代二氢咪唑并吡啶类化合物的晶型及其制备方法 |
| CA3260159A1 (en) * | 2022-06-30 | 2024-01-04 | Principia Biopharma Inc. | Therapeutic Tyrosine Kinase Inhibitors for the Treatment of Multiple Sclerosis and Myasthenia Gravis |
| US20240173313A1 (en) * | 2022-10-11 | 2024-05-30 | Genzyme Corporation | Therapeutic tyrosine kinase inhibitors for multiple sclerosis |
| US20240238267A1 (en) * | 2022-12-20 | 2024-07-18 | Genzyme Corporation | Drug formulations of (r)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-phenoxyphenyl)-1h-imidazo[4,5-c]pyridin-2(3h)-one |
| AU2024214470A1 (en) | 2023-02-01 | 2025-09-11 | Principia Biopharma Inc. | Methods of diagnosing and treating multiple sclerosis by detecting a biomarker in the cerebrospinal fluid |
| WO2025264860A2 (en) | 2024-06-18 | 2025-12-26 | Yale University | Methods of treating post-covid airway disease |
Family Cites Families (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2809918A (en) | 1955-10-17 | 1957-10-15 | Victor M Hermelin | Sustained release pharmaceutical preparations |
| DE2010416B2 (de) | 1970-03-05 | 1979-03-29 | Hoechst Ag, 6000 Frankfurt | Oral anwendbare Arzneiform mit Retardwirkung |
| US3760984A (en) | 1971-09-29 | 1973-09-25 | Alza Corp | Osmotically powered agent dispensing device with filling means |
| US4107288A (en) | 1974-09-18 | 1978-08-15 | Pharmaceutical Society Of Victoria | Injectable compositions, nanoparticles useful therein, and process of manufacturing same |
| US3952741A (en) | 1975-01-09 | 1976-04-27 | Bend Research Inc. | Controlled release delivery system by an osmotic bursting mechanism |
| US4728512A (en) | 1985-05-06 | 1988-03-01 | American Home Products Corporation | Formulations providing three distinct releases |
| US4794001A (en) | 1986-03-04 | 1988-12-27 | American Home Products Corporation | Formulations providing three distinct releases |
| US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| WO2003037890A2 (en) | 2001-11-01 | 2003-05-08 | Icagen, Inc. | Piperidines |
| CA2485641C (en) | 2002-06-06 | 2010-12-14 | Eisai Co., Ltd. | Novel condensed imidazole derivatives |
| US20060045822A1 (en) | 2004-09-01 | 2006-03-02 | Board Of Regents, The University Of Texas System | Plasma polymerization for encapsulating particles |
| AU2005284835A1 (en) | 2004-09-14 | 2006-03-23 | Novartis Vaccines And Diagnostics Inc. | Imidazoquinoline compounds |
| CA2597587A1 (en) | 2005-02-11 | 2006-08-17 | Coley Pharmaceutical Group, Inc. | Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods |
| US8846697B2 (en) | 2006-05-31 | 2014-09-30 | The Regents Of The University Of California | Purine analogs |
| EP2529621B1 (en) | 2006-09-22 | 2016-10-05 | Pharmacyclics LLC | Inhibitors of bruton's tyrosine kinase |
| TW200911803A (en) | 2007-07-16 | 2009-03-16 | Organon Nv | 6-phenyl-1H-imidazo [4,5-c] pyridine-4-carbonitrile derivatives |
| UY32138A (es) | 2008-09-25 | 2010-04-30 | Boehringer Ingelheim Int | Amidas sustituidas del ácido 2-(2,6-dicloro-fenilamino)-6-fluoro-1-metil-1h-bencimidazol-5-carboxílico y sus sales farmacéuticamente aceptables |
| US7741330B1 (en) | 2009-10-12 | 2010-06-22 | Pharmacyclics, Inc. | Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase |
| US8940725B2 (en) | 2010-05-31 | 2015-01-27 | Ono Pharmaceutical Co., Ltd. | Purinone derivative |
| MX2013013331A (es) | 2011-05-17 | 2014-10-17 | Principia Biopharma Inc | Derivados de azaindol como inhibidores de tirosina-cinasas. |
| AU2012255860C1 (en) | 2011-05-17 | 2015-12-10 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
| US9073947B2 (en) | 2011-06-10 | 2015-07-07 | Merck Patent Gmbh | Compositions and methods for the production of pyrimidine and pyridine compounds with BTK inhibitory activity |
| BR112014012727B1 (pt) | 2011-11-29 | 2022-10-25 | Ono Pharmaceutical Co., Ltd | Cloridrato de 6-amino-9-[(3r)-1-(2-butinoil)-3-pirrolidinil]-7-(4-fenoxifenil)-7,9-di-hidro-8h-puri- 8-ona e composição farmacêutica |
| US8501724B1 (en) | 2012-01-31 | 2013-08-06 | Pharmacyclics, Inc. | Purinone compounds as kinase inhibitors |
| MA37711A1 (fr) | 2012-06-04 | 2017-05-31 | Pharmacyclics Inc | Formes cristallines d'un inhibiteur de tyrosine kinase de bruton |
| JO3300B1 (ar) | 2012-06-06 | 2018-09-16 | Novartis Ag | مركبات وتركيبات لتعديل نشاط egfr |
| CN104487441B (zh) | 2012-06-18 | 2018-06-01 | 普林斯匹亚生物制药公司 | 有用于治疗癌症和自身免疫性疾病的可逆的共价吡咯并嘧啶或吡唑并嘧啶 |
| SMT201900344T1 (it) | 2012-09-10 | 2019-07-11 | Principia Biopharma Inc | Composti di pirazolopirimidina come inibitori di chinasi |
| CN102942567B (zh) | 2012-11-09 | 2017-02-08 | 诸城市浩天药业有限公司 | 吡咯并喹啉醌的二钠盐结晶 |
| KR20150084923A (ko) | 2012-11-15 | 2015-07-22 | 파마시클릭스, 인코포레이티드 | 키나제 억제제로서의 피롤로피리미딘 화합물 |
| US20140142099A1 (en) | 2012-11-20 | 2014-05-22 | Principia Biopharma Inc. | Purinone Derivatives as Tyrosine Kinase Inhibitors |
| WO2014100065A1 (en) | 2012-12-20 | 2014-06-26 | Merck Sharp & Dohme Corp. | Substituted imidazopyridines as hdm2 inhibitors |
| ME03000B (me) | 2012-12-21 | 2018-10-20 | Plexxikon Inc | Jedinjenja i metode modulacije kinaze i povezane indikacije |
| SG11201605417QA (en) | 2014-02-03 | 2016-08-30 | Cadila Healthcare Ltd | Heterocyclic compounds |
| CN107001362A (zh) | 2014-10-06 | 2017-08-01 | 默克专利有限公司 | 用作btk抑制剂的杂芳基化合物及其用途 |
| JP2016094368A (ja) | 2014-11-14 | 2016-05-26 | 大日本住友製薬株式会社 | ベンズイミダゾール化合物の新規結晶、及びその製造方法 |
| WO2016086358A1 (en) | 2014-12-02 | 2016-06-09 | Merck Sharp & Dohme Corp. | Hydroxymethyl piperidine orexin receptor antagonists |
| KR20170105021A (ko) | 2015-01-28 | 2017-09-18 | 아스테라스 세이야쿠 가부시키가이샤 | 피라진카르복사마이드 화합물의 제조 방법 및 그 합성 중간체 |
| EP3912979B1 (en) * | 2015-06-03 | 2026-03-25 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
| CN105753863B (zh) | 2015-09-11 | 2018-07-31 | 东莞市真兴贝特医药技术有限公司 | 氧代二氢咪唑并吡啶类化合物及其应用 |
| US10358446B2 (en) | 2015-10-14 | 2019-07-23 | Zibo Biopolar Changsheng Pharmaceutical Co., Ltd. | Bruton's tyrosine kinase inhibitors |
| KR102780243B1 (ko) | 2015-11-17 | 2025-03-14 | 메르크 파텐트 게엠베하 | Btk 억제 활성을 갖는 피리미딘 및 피리딘 화합물을 사용하여 다발성 경화증을 치료하는 방법 |
| EP3327134A1 (en) | 2016-11-28 | 2018-05-30 | Carsten Korth | Method and biomarkers for in vitro diagnosis of mental disorders |
| US20210113568A1 (en) | 2018-04-27 | 2021-04-22 | Ono Pharmaceutical Co., Ltd. | PREVENTIVE AND/OR THERAPEUTIC AGENT FOR AUTOIMMUNE DISEASE COMPRISING COMPOUND HAVING Btk INHIBITORY ACTIVITY AS ACTIVE INGREDIENT |
| MX2021000094A (es) * | 2018-07-20 | 2021-03-25 | Merck Patent Gmbh | Compuesto de amino-pirimidina sustituido para usarse en un metodo para tratamiento y prevencion de esclerosis multiple. |
| CA3168146A1 (en) | 2020-01-20 | 2021-07-29 | Genzyme Corporation | Therapeutic tyrosine kinase inhibitors for relapsing multiple sclerosis (rms) |
| CN115867346B (zh) | 2020-06-02 | 2025-03-14 | Gb005股份有限公司 | 激酶抑制剂 |
| WO2022081512A1 (en) | 2020-10-12 | 2022-04-21 | Synubi Pharmaceuticals Llc | Compositions and methods of treatment of neuroinflammatory diseases with bruton's tyrosine kinase inhibitors |
| CA3201936A1 (en) | 2020-12-10 | 2022-06-16 | Minhua Chen | Crystal form of tolebrutinib and preparation method thereof |
| IL303834A (en) | 2020-12-23 | 2023-08-01 | Genzyme Corp | 4-amino-3-(4-phenoxyphenyl)-1,3-dihydro-2H-imidazo[4,5-C]pyridin-2-one derivatives and their salts |
| CN117295735B (zh) | 2021-04-23 | 2026-05-12 | 杭州领业医药科技有限公司 | Tolebrutinib晶型、无定型及其制备方法和用途 |
| CN117412749A (zh) | 2021-05-21 | 2024-01-16 | 杭州领业医药科技有限公司 | Tolebrutinib盐及其晶型、其制备方法、其药物组合物和用途 |
| WO2022257845A1 (zh) | 2021-06-11 | 2022-12-15 | 苏州科睿思制药有限公司 | Tolebrutinib的晶型及其制备方法和用途 |
| IL310975A (en) | 2021-09-03 | 2024-04-01 | Novartis Ag | LOU064 for the treatment of multiple sclerosis |
| CA3241687A1 (en) | 2021-12-21 | 2023-06-29 | Tim Owens | Crystalline forms of (r)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-phenoxyphenyl)-1h-imidazo[4,5-c]pyridin-2(3h)-one and salts thereof |
| CN119212708A (zh) | 2022-05-13 | 2024-12-27 | 普林斯匹亚生物制药公司 | 用于髓鞘少突胶质细胞糖蛋白抗体疾病(mogad)的治疗性酪氨酸激酶抑制剂 |
| EP4540229A1 (en) | 2022-06-14 | 2025-04-23 | Principia Biopharma Inc. | Methods of making tolebrutinib |
| US20260022123A1 (en) | 2022-06-22 | 2026-01-22 | Principia Biopharma Inc. | Methods of Making Modified BTK Inhibitors |
| CA3260159A1 (en) | 2022-06-30 | 2024-01-04 | Principia Biopharma Inc. | Therapeutic Tyrosine Kinase Inhibitors for the Treatment of Multiple Sclerosis and Myasthenia Gravis |
| US20240173313A1 (en) | 2022-10-11 | 2024-05-30 | Genzyme Corporation | Therapeutic tyrosine kinase inhibitors for multiple sclerosis |
| US20240238267A1 (en) | 2022-12-20 | 2024-07-18 | Genzyme Corporation | Drug formulations of (r)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-phenoxyphenyl)-1h-imidazo[4,5-c]pyridin-2(3h)-one |
| AU2024214470A1 (en) | 2023-02-01 | 2025-09-11 | Principia Biopharma Inc. | Methods of diagnosing and treating multiple sclerosis by detecting a biomarker in the cerebrospinal fluid |
| US20250282777A1 (en) | 2024-03-06 | 2025-09-11 | Principia Biopharma Inc. | Methods of Making Tolebrutinib |
-
2021
- 2021-01-19 CA CA3168146A patent/CA3168146A1/en active Pending
- 2021-01-19 KR KR1020227028409A patent/KR102971371B1/ko active Active
- 2021-01-19 MX MX2022008875A patent/MX2022008875A/es unknown
- 2021-01-19 BR BR112022014058A patent/BR112022014058A2/pt unknown
- 2021-01-19 TW TW110101887A patent/TWI883107B/zh active
- 2021-01-19 WO PCT/US2021/013883 patent/WO2021150476A1/en not_active Ceased
- 2021-01-19 US US17/151,954 patent/US11969418B2/en active Active
- 2021-01-19 CN CN202180009557.XA patent/CN115348862A/zh active Pending
- 2021-01-19 EP EP21705735.5A patent/EP4093397A1/en active Pending
- 2021-01-19 JP JP2022543411A patent/JP2023510604A/ja active Pending
- 2021-01-19 IL IL294560A patent/IL294560A/en unknown
- 2021-01-19 AU AU2021209608A patent/AU2021209608B2/en active Active
-
2024
- 2024-03-22 US US18/613,641 patent/US12636280B2/en active Active
-
2025
- 2025-09-19 JP JP2025155610A patent/JP2026001038A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR102971371B1 (ko) | 2026-06-02 |
| AU2021209608A1 (en) | 2022-09-15 |
| JP2026001038A (ja) | 2026-01-06 |
| IL294560A (en) | 2022-09-01 |
| WO2021150476A1 (en) | 2021-07-29 |
| JP2023510604A (ja) | 2023-03-14 |
| US11969418B2 (en) | 2024-04-30 |
| EP4093397A1 (en) | 2022-11-30 |
| US20210244720A1 (en) | 2021-08-12 |
| KR20220130179A (ko) | 2022-09-26 |
| CN115348862A (zh) | 2022-11-15 |
| TW202140002A (zh) | 2021-11-01 |
| CA3168146A1 (en) | 2021-07-29 |
| US12636280B2 (en) | 2026-05-26 |
| BR112022014058A2 (pt) | 2022-09-13 |
| US20240366585A1 (en) | 2024-11-07 |
| AU2021209608B2 (en) | 2026-06-04 |
| TWI883107B (zh) | 2025-05-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022014058A2 (pt) | Inibidores terapêuticos de tirosina cinase para esclerose múltipla recidivante (rms) | |
| MX2025004218A (es) | Inhibidores terapéuticos de la tirosina cinasa para la esclerosis múltiple | |
| CO2022015638A2 (es) | Compuestos, composiciones farmacéuticas y métodos para la preparación de compuestos y para su uso | |
| CL2023003583A1 (es) | Inhibidores de pi3k y métodos de uso de los mismos div 2985-22 | |
| CL2022001743A1 (es) | Dosis de gamma-hidroxibutirato (ghb) | |
| CL2024001022A1 (es) | Moléculas pequeñas para el tratamiento del cáncer | |
| CL2022003510A1 (es) | Inhibidores de cisteína proteasas y sus métodos de uso | |
| CO2026004964A2 (es) | Moduladores de kras | |
| BR112022016382A2 (pt) | Triptaminas específicas para o uso no tratamento de doenças do humor | |
| UY38221A (es) | Inhibidores de proteínas ras con g12c mutantes | |
| AR116753A1 (es) | Proceso de preparación de un derivado de pirazolsulfonilamida | |
| MX2021007179A (es) | Pirazolopirimidinas sustituidas y purinas sustituidas y su uso como inhibidores de proteasa procesadora especifica de ubiquitina 1 (usp1). | |
| ECSP23057264A (es) | Inhibidores de cdk2 y métodos de uso de los mismos | |
| CR20170563A (es) | Compuestos de benzoxacepina oxazolidinona y métodos de uso. | |
| EA202092154A1 (ru) | Комбинированная терапия | |
| MX2023000812A (es) | Analogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton. | |
| AR126447A1 (es) | INHIBIDORES DE PI3Ka Y MÉTODOS DE USO DE LOS MISMOS | |
| MX2020012008A (es) | Métodos para potenciar la biodisponibilidad y la exposición de un abridor de canales de potasio dependientes de voltaje. | |
| CO2022008001A2 (es) | Métodos para el tratamiento de trastornos depresivos | |
| CL2021000580A1 (es) | Uso de inhibidores de la caseina quinasa 1 para el tratamiento de enfermedades vasculares. | |
| CL2023001637A1 (es) | Inhibidores de la vía jak1 para el tratamiento del vitíligo. | |
| CL2022002699A1 (es) | Métodos para tratar la esclerosis múltiple recidivante utilizando un inhibidor de la tirosina cinasa de bruton. | |
| CO2024009144A2 (es) | Inhibidores de cinasa met | |
| CO2023012342A2 (es) | Inhibidores de enzimas | |
| CL2021001830A1 (es) | Inhibidores de lta4h para el tratamiento de la hidradenitis supurativa |